CymaBay Therapeutics (CBAY) Sets New 12-Month Low at $7.37
CymaBay Therapeutics Inc (NASDAQ:CBAY)’s share price reached a new 52-week low on Tuesday . The stock traded as low as $7.37 and last traded at $9.60, with a volume of 3132726 shares. The stock had previously closed at $10.50.
Several equities analysts recently issued reports on the company. Oppenheimer set a $18.00 price target on CymaBay Therapeutics and gave the company a “buy” rating in a research note on Wednesday, November 7th. Cantor Fitzgerald set a $17.00 price target on CymaBay Therapeutics and gave the company a “buy” rating in a research note on Wednesday, November 7th. Zacks Investment Research upgraded CymaBay Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, November 5th. BidaskClub upgraded CymaBay Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, November 2nd. Finally, Piper Jaffray Companies boosted their price target on CymaBay Therapeutics to $30.00 and gave the company an “overweight” rating in a research note on Friday, August 10th. Two equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. CymaBay Therapeutics currently has an average rating of “Buy” and a consensus target price of $21.75.
The company has a market cap of $687.12 million, a PE ratio of -11.41 and a beta of 1.89.
In related news, CEO Sujal Shah acquired 5,000 shares of the stock in a transaction dated Monday, October 15th. The shares were bought at an average cost of $9.90 per share, for a total transaction of $49,500.00. Following the purchase, the chief executive officer now owns 100,000 shares in the company, valued at approximately $990,000. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 4.50% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. grew its position in CymaBay Therapeutics by 246.8% during the 2nd quarter. BlackRock Inc. now owns 4,054,285 shares of the biopharmaceutical company’s stock worth $54,410,000 after acquiring an additional 2,885,082 shares during the last quarter. Eagle Asset Management Inc. bought a new stake in CymaBay Therapeutics during the 2nd quarter worth approximately $27,686,000. Carillon Tower Advisers Inc. bought a new stake in CymaBay Therapeutics during the 2nd quarter worth approximately $19,422,000. Baker BROS. Advisors LP grew its position in CymaBay Therapeutics by 25.5% during the 2nd quarter. Baker BROS. Advisors LP now owns 4,917,700 shares of the biopharmaceutical company’s stock worth $65,996,000 after acquiring an additional 1,000,000 shares during the last quarter. Finally, Voya Investment Management LLC bought a new stake in CymaBay Therapeutics during the 2nd quarter worth approximately $12,667,000. Institutional investors own 95.80% of the company’s stock.
CymaBay Therapeutics Company Profile (NASDAQ:CBAY)
CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.
See Also: What is intrinsic value?
Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.